Earnings Call Summary | Hyperfine(HYPR.US) Q2 2024 Earnings Conference
Earnings Call Summary | Hyperfine(HYPR.US) Q2 2024 Earnings Conference
The following is a summary of the Hyperfine, Inc. (HYPR) Q2 2024 Earnings Call Transcript:
以下是Hyperfine股份有限公司(HYPR)2024年第二季度業績會記錄摘要:
Financial Performance:
金融業績:
Hyperfine, Inc. reported Q2 2024 revenue of $3.6 million, a 7% increase year-over-year and a 10% increase from Q1 2024.
Gross profit for Q2 2024 was $1.8 million, resulting in a record gross margin of 50%.
Net loss for Q2 2024 was $10.1 million, an improvement from Q2 2023's net loss of $10.6 million.
Company raised its full-year 2024 revenue outlook to $13 million to $16 million.
Hyperfine股份有限公司報告稱,2024年第二季度營業收入爲360萬美元,同比增長7%,比2024年第一季度增長10%。
2024年第二季度毛利潤爲180萬美元,毛利率創紀錄地達到了50%。
2024年第二季度淨虧損爲1010萬美元,比2023年第二季度的淨虧損1060萬美元有所改善。
公司將其2024年全年營業收入前景展望上調至1300萬至1600萬美元。
Business Progress:
業務進展:
Hyperfine, Inc. achieved FDA clearance for its ninth generation AI-powered software, enhancing its Swoop system's imaging capability and reducing scan times.
Initiated CARE PMR study in Alzheimer's program and began enrollment.
Presented promising data on ARIA detection with Swoop at the Alzheimer's Association International Conference.
Announced publication providing evidence of Swoop's efficacy in acute stroke detection.
Hyperfine公司的第九代AI驅動軟件經過FDA審批,增強了其Swoop系統的成像能力並縮短了掃描時間。
啓動了阿爾茨海默病計劃中的CARE PMR研究,並開始招募研究對象。
在阿爾茨海默病協會國際會議上發佈了關於Swoop的ARIA檢測的有前途的數據。
宣佈發表一篇論文,證明了Swoop在急性中風檢測方面的有效性。
Opportunities:
機會:
The company anticipates significant growth in placing Swoop systems within neurology clinics, infusion centers, and other Alzheimer's care programs starting in the second half of 2025.
Expected commercial contributions from stroke triage systems in various medical settings.
Expansion into international markets with anticipated regulatory approval in India in the second half of 2025.
Plans for entrance into neurology office settings, following expected accreditation by the end of the current year.
公司預計在2025年下半年開始大量在神經病學診所、輸液中心和其他阿爾茨海默病護理計劃中部署Swoop系統,從而實現顯著增長。
預計從各種醫療場所的中風分類系統中獲得商業貢獻。
計劃擴大到國際市場,並有望在2025年下半年獲得印度的監管批准。
計劃進入神經病學診所設置,此前有望在今年底獲得認證。
Risks:
風險:
The slow and gradual adoption of the company's AI and imaging technologies in new clinical settings and the international market may affect anticipated sales.
Dependence on regulatory approvals for market expansions, which includes obtaining necessary accreditations for new business models outside traditional hospital settings.
該公司的AI和成像技術在新的臨床設置和國際市場中的緩慢逐步採用可能會影響預期銷售額。
依賴於市場擴張的監管批准,包括在傳統醫院設置以外的新業務模式獲得必要的認證。
More details: Hyperfine IR
更多詳細信息:Hyperfine IR
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示:如需更全面的詳情,請參閱投資人關係網站。本文僅供投資者參考,不作任何指引或建議。
譯文內容由第三人軟體翻譯。